These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

58 related articles for article (PubMed ID: 15757616)

  • 1. Comparison of the safety and efficacy of emboli prevention devices versus platelet glycoprotein IIb/IIIa inhibition during carotid stenting.
    Chan AW; Yadav JS; Bhatt DL; Bajzer CT; Gum PA; Roffi M; Cho L; Agah R; Topol EJ
    Am J Cardiol; 2005 Mar; 95(6):791-5. PubMed ID: 15757616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abciximab in carotid stenting for postsurgical carotid restenosis: intermediate results.
    Schneiderman J; Morag B; Gerniak A; Rimon U; Varon D; Seligsohn U; Shotan A; Adar R
    J Endovasc Ther; 2000 Aug; 7(4):263-72. PubMed ID: 10958289
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of glycoprotein IIb/IIIa inhibitors in carotid angioplasty and stenting.
    Wholey MH; Wholey MH; Eles G; Toursakissian B; Bailey S; Jarmolowski C; Tan WA
    J Endovasc Ther; 2003 Feb; 10(1):33-41. PubMed ID: 12751927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization.
    Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L;
    N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carotid angioplasty and stent placement: a prospective analysis of perioperative complications and impact of intravenously administered abciximab.
    Qureshi AI; Suri MF; Ali Z; Kim SH; Lanzino G; Fessler RD; Ringer AJ; Guterman LR; Hopkins LN
    Neurosurgery; 2002 Mar; 50(3):466-73; discussion 473-5. PubMed ID: 11841713
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefit of bolus-only platelet glycoprotein IIb/IIIa inhibition during percutaneous coronary intervention: insights from the very early outcomes in the Evaluation of 7E3 for the Prevention of Ischemic Complications (EPIC) trial.
    Marmur JD; Mitre CA; Barnathan E; Cavusoglu E
    Am Heart J; 2006 Nov; 152(5):876-81. PubMed ID: 17070148
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Platelet glycoprotein IIb/IIIa receptor inhibition as adjunctive treatment during saphenous vein graft stenting: differential effects after randomization to occlusion or filter-based embolic protection.
    Jonas M; Stone GW; Mehran R; Hermiller J; Feldman R; Herrmann HC; Cox DA; Kuntz RE; Popma JJ; Rogers C;
    Eur Heart J; 2006 Apr; 27(8):920-8. PubMed ID: 16415300
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of low-dose unfractionated heparin during percutaneous coronary revascularisation and the relationship between activated clotting time and haemorrhagic or ischaemic complications: our results.
    Capuano C; Sesana M; Leonzi O; Cuccia C
    J Cardiovasc Med (Hagerstown); 2006 Dec; 7(12):866-71. PubMed ID: 17122672
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators.
    Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ
    N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
    Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
    N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embolic protection and platelet inhibition during renal artery stenting.
    Cooper CJ; Haller ST; Colyer W; Steffes M; Burket MW; Thomas WJ; Safian R; Reddy B; Brewster P; Ankenbrandt MA; Virmani R; Dippel E; Rocha-Singh K; Murphy TP; Kennedy DJ; Shapiro JI; D'Agostino RD; Pencina MJ; Khuder S
    Circulation; 2008 May; 117(21):2752-60. PubMed ID: 18490527
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience of platelet glycoprotein IIb/IIIa inhibition with abciximab during carotid stenting: a safe and effective adjunctive therapy.
    Kapadia SR; Bajzer CT; Ziada KM; Bhatt DL; Wazni OM; Silver MJ; Beven EG; Ouriel K; Yadav JS
    Stroke; 2001 Oct; 32(10):2328-32. PubMed ID: 11588321
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcome of access site in patients treated with platelet glycoprotein IIb/IIIa inhibitors in the era of closure devices.
    Assali AR; Sdringola S; Moustapha A; Ghani M; Salloum J; Schroth G; Fujise K; Anderson HV; Smalling RW; Rosales OR
    Catheter Cardiovasc Interv; 2003 Jan; 58(1):1-5. PubMed ID: 12508187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits and risks of abciximab use in primary angioplasty for acute myocardial infarction: the Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) trial.
    Tcheng JE; Kandzari DE; Grines CL; Cox DA; Effron MB; Garcia E; Griffin JJ; Guagliumi G; Stuckey T; Turco M; Fahy M; Lansky AJ; Mehran R; Stone GW;
    Circulation; 2003 Sep; 108(11):1316-23. PubMed ID: 12939213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombocytopenia caused by abciximab or tirofiban and its association with clinical outcome in patients undergoing coronary stenting.
    Merlini PA; Rossi M; Menozzi A; Buratti S; Brennan DM; Moliterno DJ; Topol EJ; Ardissino D
    Circulation; 2004 May; 109(18):2203-6. PubMed ID: 15117843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The PROFI study (Prevention of Cerebral Embolization by Proximal Balloon Occlusion Compared to Filter Protection During Carotid Artery Stenting): a prospective randomized trial.
    Bijuklic K; Wandler A; Hazizi F; Schofer J
    J Am Coll Cardiol; 2012 Apr; 59(15):1383-9. PubMed ID: 22284330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Intracranial hemorrhage and hyperperfusion syndrome following carotid artery stenting: risk factors, prevention, and treatment.
    Abou-Chebl A; Yadav JS; Reginelli JP; Bajzer C; Bhatt D; Krieger DW
    J Am Coll Cardiol; 2004 May; 43(9):1596-601. PubMed ID: 15120817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of glycoprotein IIb-IIIa receptor antagonism on platelet membrane glycoproteins after coronary stent placement.
    Gawaz M; Ruf A; Neumann FJ; Pogátsa-Murray G; Dickfeld T; Zohlnhöfer D; Schömig A
    Thromb Haemost; 1998 Dec; 80(6):994-1001. PubMed ID: 9869173
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.